✦ LIBER ✦

P-359 Results from a phase I study of the oral VEGF receptor tyrosine kinase inhibitor ZD6474, in patients with solid tumors

✍ Scribed by Wheeler, Catherine; Minami, Hironobu; Ebi, Hiromichi; Tahara, Makoto; Sasaki, Yasutsuna; Yamamoto, Noboru; Yamada, Yasuhide; Tamura, Tomohide; Saijo, Nagahiro

Book ID: 118572059
Publisher: Elsevier Science
Year: 2003
Tongue: English
Weight: 189 KB
Volume: 41
Category: Article
ISSN: 0169-5002
DOI: 10.1016/s0169-5002(03)92327-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Effects of ZD6474, an orally active inhi

Effects of ZD6474, an orally active inhibitor of VEGF receptor tyrosine kinase, in patients with solid tumors: Results from a phase I study

✍ S. Holden; S. Eckhardt; R. Basser; D. Rischin; H. Hurwitz; R. DeBoer; M. Rosenth 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 189 KB

Phase I clinical trial of CEP-2563 dihyd

Phase I clinical trial of CEP-2563 dihydrochloride, a receptor tyrosine kinase inhibitor, in patients with refractory solid tumors

✍ Samir D. Undevia; Nicholas J. Vogelzang; Ann M. Mauer; Linda Janisch; Sridhar Ma 📂 Article 📅 2004 🏛 Springer US 🌐 English ⚖ 147 KB

Phase I dose-finding and pharmacokinetic

Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumors

✍ Noboru Yamamoto; Atsushi Horiike; Yasuhito Fujisaka; Haruyasu Murakami; Tatsu Sh 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 367 KB

Phase I and pharmacokinetic study of TSU

Phase I and pharmacokinetic study of TSU-68, a novel multiple receptor tyrosine kinase inhibitor, by twice daily oral administration between meals in patients with advanced solid tumors

✍ Yutaka Ueda; Tatsu Shimoyama; Haruyasu Murakami; Noboru Yamamoto; Yasuhide Yamad 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 472 KB

137 A phase I study of an oral vascular

137 A phase I study of an oral vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor, CP-547,632, in patients with advanced solid tumors

✍ Tolcher, A.; O'Leary, J.J.; DeBono, J.; Molpus, K.; Woodard, C.; Warnat, M.; Lia 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 148 KB

108 POSTER Phase I study of ABT869, a mu

108 POSTER Phase I study of ABT869, a multiple receptor tyrosine kinase inhibitor, in patients with refractory solid malignancies.

✍ B.C. Goh; C.H. Thang; N. Sukri; C.I. Wong; R. Soo; R. Carr; S.C. Lee; C.S. Chen; 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 62 KB